Brief: I-Mab Doses Patient In Phase 1 Clinical Trial Of Claudin 18.2, 4-1BB Bispecific Antibody TJ-CD4B In Solid Tumors

NovaBridge Biosciences

22/07/2022 13:04

July 22 (Reuters) - I-Mab  IMAB.O :
    * I-MAB ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL
TRIAL OF
CLAUDIN 18.2 AND 4-1BB BISPECIFIC ANTIBODY TJ-CD4B IN SOLID
TUMORS IN CHINA

Source text for Eikon:  ID:nPnL4bsja 
Further company coverage:  IMAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))